Today approved Provenge The US Food and Drug Administration, a first-of-a kind vaccine for the treatment of prostate cancer. The treatment proved to extend lifespan by more than four a few months normally. All told, that’s not a bad deal when comparing the price compared to that of other tumor meds.For the first one fourth of 2012, corporate partner revenues had been $3 million, in comparison to $15 million in the initial quarter of 2011. Up to date 2012 Financial Assistance Biogen Idec updated the full year 2012 economic guidance also. Price of Sales is likely to be around 9 percent to 10 percent of total income. R&D expense is likely to be around 24 percent to 25 percent of total income. SG&A expense is likely to be around 22 percent to 23 percent of total revenue. Tax expenditure is likely to be around 24 percent to 25 percent of pretax income. Non-GAAP diluted EPS is certainly likely to be above $6.15.